Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3537.73% is 33988% below its 5-year average of -10.38%, near the low end of its 5-year range (-4762.03%–81.08%).
2.48% below its 12-month average of -3452.18%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -4762.03%.
NET PROFIT MARGIN
-3537.73%
NET PROFIT MARGIN AVG TTM
-3452.18%
NET PROFIT MARGIN AVG 3Y
-1338.50%
NET PROFIT MARGIN AVG 5Y
-10.38%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.48%
CURRENT VS 3Y AVG
-164.30%
CURRENT VS 5Y AVG
-33987.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-1360565.38%
vs the sector median at left
Entrada Therapeutics, Inc.
Market Cap
$210.80M
Net Profit Margin
-3537.73%
TTM Avg
-3452.18%
3Y Avg
-1338.50%
5Y Avg
-10.38%
Market Cap
$210.85M
Net Profit Margin
47.55%
TTM Avg
-1.25%
3Y Avg
-126.95%
5Y Avg
-427.13%
Market Cap
$210.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$212.22M
Net Profit Margin
12.39%
TTM Avg
11.00%
3Y Avg
-1.71%
5Y Avg
-13.45%
Market Cap
$208.48M
Net Profit Margin
74.06%
TTM Avg
51.52%
3Y Avg
44.79%
5Y Avg
47.28%
Market Cap
$213.63M
Net Profit Margin
-920285.19%
TTM Avg
-662320.41%
3Y Avg
-376335.80%
5Y Avg
-251721.50%
Market Cap
$207.70M
Net Profit Margin
17.62%
TTM Avg
15.55%
3Y Avg
12.60%
5Y Avg
12.03%
Market Cap
$206.40M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.21M
Net Profit Margin
-269.75%
TTM Avg
-1318.17%
3Y Avg
-659.09%
5Y Avg
-439.39%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.80M | -3537.73% | -3452.18% | -1338.50% | -10.38% |
| Compugen Ltd. (CGEN)vs › | $210.85M | 47.55% | -1.25% | -126.95% | -427.13% |
| Sionna Therapeutics, Inc. (SION)vs › | $210.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Niagen Bioscience Inc (NAGE)vs › | $212.22M | 12.39% | 11.00% | -1.71% | -13.45% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $208.48M | 74.06% | 51.52% | 44.79% | 47.28% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.63M | -920285.19% | -662320.41% | -376335.80% | -251721.50% |
| Pro-Dex, Inc. (PDEX)vs › | $207.70M | 17.62% | 15.55% | 12.60% | 12.03% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.40M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.21M | -269.75% | -1318.17% | -659.09% | -439.39% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.23M | -288.26% | -266.69% | -300.28% | -1842.40% |
Operating Margin
-613.7%
Net Profit Margin
-3537.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -4762.03% |
| 2026-03-31 | -4539.09% |
| 2025-12-31 | -3014.93% |
| 2025-09-30 | -2734.45% |
| 2025-06-30 | -2210.41% |
| 2025-03-31 | -84.39% |
| 2024-12-31 | 3.02% |
| 2024-09-30 | -71.70% |
| 2024-06-30 | 58.11% |
| 2024-03-31 | 39.74% |
| 2023-12-31 | -22.81% |
| 2023-09-30 | 81.08% |
| 2023-06-30 | -142.70% |
| 2023-03-31 | -26.42% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
